An evidence-based approach to COPD: Part 1 - A review of current guidelines on the diagnosis and management of chronic obstructive pulmonary disease. the first of a two-part article

American Journal of Nursing

Volumn 112, Issue 3, 2012, Pages 46-57

  Corbridge, Susan ^a   Wilken, Lori ^a   Kapella, Mary C ^a   Gronkiewicz, Cindy ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

chronic bronchitis; chronic obstructive pulmonary disease; emphysema; patient education; respiratory disease

Indexed keywords

BRONCHODILATING AGENT;

CHRONIC OBSTRUCTIVE LUNG DISEASE; HUMAN; LUNG VOLUME; REVIEW;

BRONCHODILATOR AGENTS; HUMANS; LUNG VOLUME MEASUREMENTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84858294435     PISSN: 0002936X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAJ.0000412639.08764.21     Document Type: Review

References (60)

1. Jones PW, et al. Development and first validation of the COPD Assessment Test. Eur Respir J 2009;34(3):648-54.
2. Mannino DM, et al. Chronic obstructive pulmonary disease surveillance-United States, 1971-2000. MMWR Surveill Summ 2002;51(6):1-16.
3. Kochanek KD, et al. Deaths: Preliminary data for 2009. Hyattsville, MD: National Center for Health Statistics; 2011 Mar 16. National vital statistics reports; vol 59, no. 4; http:// www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59-04.pdf.
4. American Thoracic Society, European Respiratory Society. Standards for the diagnosis and management of patients with COPD. New York; Lausanne, Switzerland; 2004. http://www. thoracic.org/clinical/copd-guidelines/resources/ copddoc. pdf.
5. Eisner MD, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182(5):693-718.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2010); 2010. http://www.goldcopd.org/uploads/ users/files/GOLDReport-April112011.pdf.
7. Forey BA, et al. Systematic review with meta-Analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema. BMC Pulm Med 2011; 11:36.
8. Zielinski J, Bednarek M. Early detection of COPD in a highrisk population using spirometric screening. Chest 2001; 119(3):731-6. (Pubitemid 32197641)
9. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society statement: Standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med 2003;168(7):818-900.
10. Stoller JK, Aboussouan LS. Alpha1-Antitrypsin deficiency. Lancet 2005;365(9478):2225-36.
11. Rodriguez-Roisin R. The airway pathophysiology of COPD: Implications for treatment. COPD 2005;2(2):253-62. (Pubitemid 40993300)
12. Lang MR, et al. Collagen content of alveolar wall tissue in emphysematous and non-emphysematous lungs. Thorax 1994;49(4):319-26. (Pubitemid 24149193)
13. Kleinschmidt P. Chronic obstructive pulmonary disease and emphysema in emergency medicine. New York: Medscape. com 2011.
14. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33(5):1165-85.
15. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011;139(1):165-73.
16. Fimognari FL, et al. Mechanisms of atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008;3(1):89-96. (Pubitemid 351523720)
17. Qaseem A, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155(3): 179-91.
18. GlaxoSmithKline. CAT: COPD assessment test. Research Triangle Park, NC; 2009 Sep. Healthcare professional user guide; http://www.catestonline.org/ images/UserGuides/ CATHCPUser%20guideEn.pdf.
19. Celli BR, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350(10):1005-12. (Pubitemid 38269277)
20. Baltzan MA, et al. Fatigue in COPD: Prevalence and effect on outcomes in pulmonary rehabilitation. Chron Respir Dis 2011;8(2):119-28.
21. Kapella MC, et al. Subjective fatigue, influencing variables, and consequences in chronic obstructive pulmonary disease. Nurs Res 2006;55(1):10-7. (Pubitemid 44492147)
22. Baghai-Ravary R, et al. Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. Respir Med 2009;103(2):216-23.
23. GlaxoSmithKline. Prescribing information: Ventolin HFA (albuterol sulfate) inhalation aerosol. Research Triangle Park, NC; 2008. http://www.accessdata.fda.gov/drugsatfda-docs/ label/2008/020983s016lbl.pdf.
24. Lee TA, et al. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med 2008;149(6):380-90.
25. Singh S, et al. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: A systematic review and meta-Analysis. JAMA 2008;300(12):1439-50.
26. Macie C, et al. Cardiovascular morbidity and the use of inhaled bronchodilators. Int J Chron Obstruct Pulmon Dis 2008;3(1):163-9. (Pubitemid 351523729)
27. Ogale SS, et al. Cardiovascular events associated with ipratropium bromide in COPD. Chest 2010;137(1):13-9.
28. Rutten FH, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170(10):880-7.
29. GlaxoSmithKline. Medication guide: Serevent Diskus (salmeterol xinafoate inhalation powder). Research Triangle Park, NC; 2010. http://www.fda.gov/ downloads/Drugs/DrugSafety/ ucm089125.pdf.
30. van Noord JA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15(5):878-85. (Pubitemid 30321844)
31. Schering Corporation. Medication guide: Foradil Aerolizer (formoterol fumarate inhalation powder). Whitehouse Station, NJ; 2011. http://www.fda.gov/ downloads/Drugs/DrugSafety/ ucm088602.pdf.
32. DEY Pharma. Prescribing information: Perforomist (formoterol fumarate) inhalation solution. Napa, CA; 2010. http://www.perforomist.com/pdf/Perforomist- Prescribing-Information.pdf.
33. Vogelmeier C, et al. Indacaterol provides 24-hour bronchodilation in COPD: A placebo-controlled blinded comparison with tiotropium. Respir Res 2010;11:135.
34. Dahl R, et al. Efficacy of a new once-daily long-Acting inhaled beta2-Agonist indacaterol versus twice-daily formoterol in COPD. Thorax 2010;65(6):473-9.
35. Casaburi R, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19(2):217-24. (Pubitemid 34162820)
36. Vincken W, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19(2):209-16. (Pubitemid 34162819)
37. Donohue JF, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122(1):47-55. (Pubitemid 34754142)
38. Kerstjens HA, et al. Effects of short-Acting bronchodilators added to maintenance tiotropium therapy. Chest 2007;132(5): 1493-9. (Pubitemid 350156004)
39. Celli B, et al. Cardiovascular safety of tiotropium in patients with COPD. Chest 2010;137(1):20-30.
40. de Luise C, et al. Cardiovascular and respiratory hospitalizations and mortality among users of tiotropium in Denmark. Eur J Epidemiol 2007;22(4):267-72. (Pubitemid 46733877)
41. Tashkin DP, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359(15): 1543-54.
42. Ford PA, et al. Treatment effects of low-dose theophylline combined with an inhaled corticosteroid in COPD. Chest 2010;137(6):1338-44.
43. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Summary handout: Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (revised 2011); 2011. http://www.goldcopd. org/uploads/users/files/GOLD2011-Summary.pdf.
44. Calverley PM, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356(8):775-89. (Pubitemid 46294610)
45. Wedzicha JA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177(1):19-26.
46. Singh D, et al. Superiority of "triple" therapy with salmeterol/ fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63(7):592-8. (Pubitemid 351969251)
47. Forest Pharmaceuticals. Medication guide: Daliresp (roflumilast) tablets. St. Louis; 2011. http://www.daliresp.com/ Assets/pdf/Daliresp-Medication-Guide. pdf.
48. U.S. Food and Drug Administration. FDA approves new drug to treat chronic obstructive pulmonary disease [press release]. 2011 Mar 1. http://www.fda.gov/ NewsEvents/Newsroom/ PressAnnouncements/ucm244989.htm.
49. Davies L, et al. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: A prospective randomised controlled trial. Lancet 1999;354(9177):456-60. (Pubitemid 29368923)
50. Aaron SD, et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003;348(26):2618-25. (Pubitemid 36741589)
51. Rothberg MB, et al. Antibiotic therapy and treatment failure in patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. JAMA 2010;303(20): 2035-42.
52. Nichol KL, et al. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331(12):778-84. (Pubitemid 24284768)
53. Nuorti JP, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000;342(10):681-9. (Pubitemid 30131420)
54. Centers for Disease Control and Prevention. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep 2010;59(34):1102-6.
55. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial. Ann Intern Med 1980;93(3):391-8.
56. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981;1(8222):681-6.
57. Hodgkin JE, et al. American Thoracic Society. Medical Section of the American Lung Association. Pulmonary rehabilitation. Am Rev Respir Dis 1981;124(5):663-6.
58. Troosters T, et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172(1):19-38. (Pubitemid 40923311)
59. Crapo JD, et al., editors. Baum's textbook of pulmonary diseases. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2004.
60. Johnson BD, Weisman IM. Clinical exercise testing. In: Crapo JD, et al., editors. Baum's textbook of pulmonary diseases. 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2004.